EClinicalMedicine
2026
Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, Alisson M Paredes Naveda et al.
5 citations
Sleep disturbances are common in individuals with substance use disorders (SUDs), often persisting beyond initial abstinence and hindering recovery. However, the underlying sleep abnormalities warrant further investigation, particularly given mixed findings regarding specific substances. This systematic review and meta-analysis aimed to identify sleep-related abnormalities associated with...
Spiral (Imperial College London)
December 30, 2025
Rayyan Zafar
Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of...
International Journal of Endovascular Treatment and Innovative Techniques
December 26, 2025
Km Megha, Arjun Ram Roj, Vijay Shanker Yadav et al.
Background: Addiction is a multifaceted disorder involving compulsive substance use, impaired self-regulation, and continued use despite adverse consequences. Neurobiological alterations in key brain regions, including the Prefrontal Cortex (PFC), amygdala, hippocampus, and mesolimbic reward system, underlie addiction pathophysiology. These changes disrupt reward processing, cognitive control,...
Psychedelic Medicine
December 26, 2025
Rhianna Rich, Kelsey T. Laird, Prabha Siddarth et al.
Background: Psychedelic-assisted psychotherapy has shown promising results for treating alcohol use disorder (AUD) and other mental health conditions. Although the precise mechanisms of psychedelic therapies remain unclear, many studies report increased feelings of connectedness following psychedelic experiences. Specifically, both nature relatedness (one’s subjective sense of being connected...
Substance Use & Misuse
December 17, 2025
Markus D Moore, Andrew Moore, Saeed K Alzghari
Ibogaine is an interesting candidate that needs further study to determine its safety and potential for treating opioid dependence.
Current Pain and Headache Reports
December 15, 2025
Alan D. Kaye, Madison C Wolf, Sarah I Dufour et al.
2 citations
Chronic pain and opioid use disorder (OUD) are highly prevalent and frequently co-occurring conditions that pose complex treatment challenges. While opioids are effective for pain management, prolonged use significantly enhances risk of developing substance dependence. Conversely, addiction-focused therapies often fail to relieve persistent somatic pain. Ketamine, an N-methyl-D-aspartate (NMDA)...
Contemporary Family Therapy
December 11, 2025
Samuel Hosford, Heather Austin-Robillard
Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also inflicts problems for those around the user. In couples where drug abuse is present, negative codependent characteristics can arise independently in the non-user, having a damaging effect on the couple dynamic. This is a narrative review to identify how...
Addiction
December 10, 2025
John Marsden, Michael Kelleher, Fiona Dunbar et al.
2 citations
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT). Design Open‐label,...
Qeios
December 9, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to prevent relapse. At the same time, psilocybin is increasingly being investigated for the treatment of various substance use disorders. This review aims to evaluate the results of the most recent clinical trials assessing psilocybin as a treatment for...
Molecular Psychiatry
December 1, 2025
Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al.
Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of...